FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced its participation at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany (March 26-28, 2025). Dr. Hamid Khoja, Chief Scientific Officer, will present on the company's fibroblast cell-based approach for treating chronic diseases.
The presentation, titled 'Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation', will take place on March 27, 2025, from 10:25 a.m. to 12:00 p.m. Central European Time at Otto-Krayer Haus.
FibroBiologics specializes in developing therapeutics using fibroblasts and fibroblast-derived materials, with applications across multiple conditions including:
- Disc degeneration
- Orthopedics
- Multiple sclerosis
- Psoriasis
- Wound healing
- Organ involution reversal
- Cancer
FibroBiologics (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica con oltre 160 brevetti, ha annunciato la sua partecipazione al German-Nordic Joint Extracellular Matrix Meeting a Friburgo, Germania (26-28 marzo 2025). Il Dott. Hamid Khoja, Chief Scientific Officer, presenterà l'approccio dell'azienda basato sulle cellule fibroblastiche per il trattamento delle malattie croniche.
La presentazione, intitolata 'Trattamento Potenziale delle Malattie Croniche con l'Obiettivo di Mantenere l'Equilibrio del Sistema Immunitario Piuttosto che la Deplezione o l'Over-activazione', avrà luogo il 27 marzo 2025, dalle 10:25 alle 12:00 ora dell'Europa centrale presso l'Otto-Krayer Haus.
FibroBiologics si specializza nello sviluppo di terapie utilizzando fibroblasti e materiali derivati dai fibroblasti, con applicazioni in diverse condizioni tra cui:
- Degenerazione del disco
- Ortopedia
- Sclerosi multipla
- Psoriasi
- Guarigione delle ferite
- Reversibilità dell'involuzione degli organi
- Cancro
FibroBiologics (Nasdaq: FBLG), una empresa de biotecnología en etapa clínica con más de 160 patentes, anunció su participación en la Reunión Conjunta de Matriz Extracelular Germano-Nórdica en Friburgo, Alemania (26-28 de marzo de 2025). El Dr. Hamid Khoja, Director Científico, presentará el enfoque de la empresa basado en células fibroblásticas para el tratamiento de enfermedades crónicas.
La presentación, titulada 'Tratamiento Potencial de Enfermedades Crónicas con el Objetivo de la Homeostasis del Sistema Inmunológico en Lugar de la Depleción o la Sobre-activación', se llevará a cabo el 27 de marzo de 2025, de 10:25 a.m. a 12:00 p.m. Hora Central Europea en Otto-Krayer Haus.
FibroBiologics se especializa en el desarrollo de terapias utilizando fibroblastos y materiales derivados de fibroblastos, con aplicaciones en múltiples condiciones que incluyen:
- Degeneración del disco
- Ortopedia
- Esclerosis múltiple
- Psoriasis
- Sanación de heridas
- Reversibilidad de la involución de órganos
- Cáncer
FibroBiologics (Nasdaq: FBLG), 160개 이상의 특허를 보유한 임상 단계의 생명공학 회사가 독일 프라이부르크에서 열리는 독일-노르딕 공동 세포외 기질 회의에 참가한다고 발표했습니다 (2025년 3월 26-28일). 하미드 코자 박사, 최고 과학 책임자가 만성 질환 치료를 위한 회사의 섬유아세포 기반 접근법에 대해 발표할 예정입니다.
발표 제목은 '면역 체계 항상성을 유지하기 위한 만성 질환의 잠재적 치료법, 고갈 또는 과도한 활성화를 목표로 하지 않음'이며, 2025년 3월 27일 중앙 유럽 시간으로 오전 10시 25분부터 오후 12시까지 오토-크레이어 하우스에서 진행됩니다.
FibroBiologics는 섬유아세포 및 섬유아세포 유래 물질을 사용하여 치료제를 개발하는 데 전문화되어 있으며, 여러 조건에 대한 응용 프로그램을 가지고 있습니다:
- 디스크 퇴행
- 정형외과
- 다발성 경화증
- 건선
- 상처 치유
- 장기 퇴행 역전
- 암
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique avec plus de 160 brevets, a annoncé sa participation à la Réunion conjointe germano-nordique sur la matrice extracellulaire à Fribourg, en Allemagne (26-28 mars 2025). Dr. Hamid Khoja, Directeur scientifique, présentera l'approche de l'entreprise basée sur les cellules fibroblastiques pour le traitement des maladies chroniques.
La présentation, intitulée 'Traitement potentiel des maladies chroniques visant l'homéostasie du système immunitaire plutôt que la déplétion ou la suractivation', aura lieu le 27 mars 2025, de 10h25 à 12h00 heure d'Europe centrale à l'Otto-Krayer Haus.
FibroBiologics se spécialise dans le développement de thérapies utilisant des fibroblastes et des matériaux dérivés des fibroblastes, avec des applications dans plusieurs conditions, y compris:
- Dégénérescence discale
- Orthopédie
- Sclérose en plaques
- Psoriasis
- Cicatrisation des plaies
- Inversion de l'involution des organes
- Cancer
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase mit über 160 Patenten, gab seine Teilnahme an dem Deutsch-Nordischen Gemeinsamen Treffen zur Extrazellulären Matrix in Freiburg, Deutschland (26.-28. März 2025) bekannt. Dr. Hamid Khoja, Chief Scientific Officer, wird den Ansatz des Unternehmens zur Behandlung chronischer Erkrankungen auf Basis von Fibroblasten vorstellen.
Die Präsentation mit dem Titel 'Potenzielle Behandlung chronischer Erkrankungen mit dem Ziel der Homöostase des Immunsystems statt Depletion oder Überaktivierung' findet am 27. März 2025 von 10:25 bis 12:00 Uhr Mitteleuropäischer Zeit im Otto-Krayer Haus statt.
FibroBiologics ist auf die Entwicklung von Therapeutika spezialisiert, die Fibroblasten und aus Fibroblasten abgeleitete Materialien verwenden, mit Anwendungen in verschiedenen Bereichen, darunter:
- Diskusdegeneration
- Orthopädie
- Multiple Sklerose
- Psoriasis
- Wundheilung
- Rückbildung der Organe
- Krebs
- None.
- None.
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellular matrix biology.
Dr. Khoja commented, “Fibroblasts are a critical component of the extracellular matrix with regenerative and immunomodulatory properties. Our presentation will detail the progress we’ve made in expanding our portfolio and targeting additional indications by leveraging the unique potential of fibroblasts.”
Details of the conference and presentations are as follows:
The German-Nordic Joint Extracellular Matrix Meeting
Presentation Title: Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation.
Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics
Location: Otto-Krayer Haus, Albertstrasse 25, Freiburg, Germany
Date and Time: Thursday, March 27, at 10:25 a.m. to 12:00 p.m. Central European Time
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What will FibroBiologics (FBLG) present at the German-Nordic Joint ECM Meeting 2025?
How many patents does FibroBiologics (FBLG) currently hold?
What medical conditions is FibroBiologics (FBLG) targeting with their fibroblast technology?
When and where will FibroBiologics (FBLG) make their presentation in Germany?
What is unique about FibroBiologics' (FBLG) therapeutic approach?
